title: A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma.
abstract: Twenty-eight dogs with lymphoma were treated with a 12-week, 5-drug chemotherapy protocol concluding with high-dose cyclophosphamide supported by autologous bone marrow transplants. A dose escalation design was used to determine the maximum tolerated cyclophosphamide dose (MTD) in this setting. Three cyclophosphamide dose levels were given: 300 mg/ m2 IV (groupl, 3 dogs), 400 mg/m2 IV (group 2, 12 dogs), and 500 mg/m2 IV (group 3, 13 dogs); and the MTD was 500 mg/m2 IV. Toxicity was common but mild, and the dose-limiting toxicity was myelosuppression, specifically neutropenia. No dog died as a result of treatment-related toxicity. One dog in group 3 developed fever, neutropenia, and presumed sepsis and responded promptly to routine management. No other dog required hospitalization. Lower stage and higher cyclophosphamide dose (both increasing dose [study groups 1-3], and the highest dose [group 3]) compared with the lower doses combined (groups 1 and 2) were significantly associated with longer remission duration (all P < .0001). Median remission duration for dogs in group 3 was 54 weeks, compared with 21 weeks for dogs in groups 1 and 2 combined. Factors associated with longer survival time were lower stage (P = .042) and higher cyclophosphamide dose (both increasing dose [study groups 1-3], and the highest dose [group 3] compared with the lower doses combined [groups 1 and 2]) (P = .027). Median survival time for dogs in group 3 was 139 weeks, compared with 43 weeks and 68 weeks for dogs in groups 1 and 2, respectively.
authors.affiliation: Tufts University School of Veterinary Medicine, North Grafton, MA 01536, USA. voc@vetoncologyconsults.com
authors.forename: Angela E
authors.initials: AE
authors.lastname: Frimberger
authors.forename: Antony S
authors.initials: AS
authors.lastname: Moore
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Rassnick
authors.forename: Susan M
authors.initials: SM
authors.lastname: Cotter
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: O'Sullivan
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Quesenberry
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy* / Q000601:surgery*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D008223:Lymphoma / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D008297:Male; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents